What is the official website of Novartis Slovakia ?

The official website of Novartis Slovakia is https://www.novartis.com/sk-sk/pravidla-pre-komunitu-spolocnosti-novartis-pre-linkedin.

What is Novartis Slovakia's cybersecurity risk score?

Novartis Slovakia has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Slovakia experienced?

According to Rankiteo, Novartis Slovakia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Slovakia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Slovakia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Slovakia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Slovakia is not certified under SOC 2 Type 1.

Does Novartis Slovakia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Slovakia does not hold a SOC 2 Type 2 certification.

Does Novartis Slovakia comply with GDPR ?

According to Rankiteo, Novartis Slovakia is not listed as GDPR compliant.

Does Novartis Slovakia have PCI DSS certification ?

According to Rankiteo, Novartis Slovakia does not currently maintain PCI DSS compliance.

Does Novartis Slovakia comply with HIPAA ?

According to Rankiteo, Novartis Slovakia is not compliant with HIPAA regulations.

Does Novartis Slovakia have ISO 27001 certification ?

According to Rankiteo,Novartis Slovakia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Slovakia operate in ?

Novartis Slovakia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Slovakia have ?

Novartis Slovakia employs approximately 59 people worldwide.

Does Novartis Slovakia own any subsidiaries ?

Novartis Slovakia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Slovakia have ?

Novartis Slovakia's official LinkedIn profile has approximately 3,510 followers.

What is the NAICS classification code for Novartis Slovakia ?

Novartis Slovakia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Slovakia have a Crunchbase profile ?

No, Novartis Slovakia does not have a profile on Crunchbase.

Does Novartis Slovakia have a LinkedIn profile ?

Yes, Novartis Slovakia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-slovakia.

How many cybersecurity incidents has Novartis Slovakia experienced ?

As of August 19, 2026, Rankiteo reports that Novartis Slovakia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Slovakia have ?

Novartis Slovakia has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Slovakia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Slovakia

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Slovakia Vendor Cyber Rating & Cyber Score

https://www.novartis.com/sk-sk/pravidla-pre-komunitu-spolocnosti-novartis-pre-linkedin

Add Your Compliance Badge

Sme globálnou farmaceutickou spoločnosťou, ktorá pôsobí v 140 krajinách sveta a zamestnáva približne 125-tisíc ľudí. V našej snahe nájsť nové lieky sa nachádzame medzi poprednými svetovými spoločnosťami, ktoré investujú do výskumu a vývoja. Naším poslaním je objavovať nové riešenia, ktoré zlepšujú a predlžujú život pacientov. Naše produkty užíva celosvetovo miliarda ľudí a hľadáme inovatívne spôsoby, ako rozšíriť prístup k našej liečbe. Na Slovensku prinášame liečbu v rámci kardiológie, imunológie, dermatológie, neurológie, oftalmológie, respirológie, onkológie a génovej terapie. We are leading a global pharmaceutical company, employing more than 125 000 people in 140 countries all around the world. In our quest to find new medicines, we

Novartis Slovakia A.I CyberSecurity Scoring

Scoring History

Novartis Slovakia

Novartis Slovakia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Slovakia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Slovakia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Slovakia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Slovakia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Slovakia in 2026.

Incident Types Novartis Slovakia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Slovakia in 2026.

Incident History - Novartis Slovakia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Slovakia Subsidiaries

Novartis Slovakia

Pharmaceutical Manufacturing

Website: https://www.novartis.com/sk-sk/pravidla-pre-komunitu-spolocnosti-novartis-pre-linkedin

Company Size: 59

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Loading…

Novartis Slovakia Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Loading…

NEWS

Novartis Slovakia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-66591

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in David Lingren Media LIbrary Assistant allows Stored XSS. This issue affects Media LIbrary Assistant: from n/a through 3.39.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

2.3

REFERENCES

https://patchstack.com/database/wordpress/plugin/media-library-assistant/vulnerability/wordpress-media-library-assistant-plugin-3-39-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-66589

SUMMARY

Missing Authorization vulnerability in Kings Plugins B2BKing allows Exploiting Incorrectly Configured Access Control Security Levels. This issue affects B2BKing: from n/a through 5.2.30.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://patchstack.com/database/wordpress/plugin/b2bking-wholesale-for-woocommerce/vulnerability/wordpress-b2bking-plugin-5-2-30-broken-access-control-vulnerability?_s_id=cve

CVE-2026-27365

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in PublishPress PublishPress Series allows Stored XSS. This issue affects PublishPress Series: from n/a through 2.17.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

1.7

REFERENCES

https://patchstack.com/database/wordpress/plugin/organize-series/vulnerability/wordpress-publishpress-series-plugin-2-17-0-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-73974

SUMMARY

linuxfabrik-lib provides Python modules for database access, caching, shell execution, and API integrations, and Linuxfabrik Monitoring Plugins uses its shared testing helper across check plugins. Prior to linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0, lib.lftest.test() treated the first or second element of a --test CSV argument as a filesystem path and returned the file contents as simulated standard output or standard error without path confinement. The hidden but production-accessible --test argument was accepted by sudo-authorized plugins, so an attacker controlling the nagios or icinga account could use check-plugins/deb-updates/deb-updates with its default QUERY=1 to disclose every line of a root-readable file. Approximately 22 other plugins exposed filtered content or a root file existence and readability oracle through the same helper, while check-plugins/network-bonding/network-bonding and check-plugins/openstack-swift-stat/openstack-swift-stat had direct read paths that bypassed the helper. The library fix confines fixture reads to the invoking plugin's unit-test directory and refuses unsafe anchors, and the plugin fix routes the two bypasses through that helper. These issues are fixed in linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-73973

SUMMARY

Linuxfabrik Monitoring Plugins provides monitoring plugins for Icinga, Nagios, and related systems. Prior to version 7.0.0, check-plugins/logfile/logfile accepted a free-form --filename path and opened it as root when invoked through the shipped nagios or icinga sudoers allowlist, without confining the resolved path to /var/log. An attacker who controls the monitoring account can select a root-readable file such as /etc/shadow and use --warning-regex . while leaving SUPPRESS_OUTPUT false, causing each nonempty line to be collected in warn_matches and returned through lib.base.oao(). The vulnerable flow passes the expanded scan_path directly to open(), and neither real-path containment nor an allowlist protects the sink. The same fix also confines mysql-logfile and openvpn-client-list paths, allows only documented log roots, and resolves symlinks and parent-directory traversal before checking containment. This issue is fixed in version 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…